Cerus Corp
NASDAQ:CERS

Watchlist Manager
Cerus Corp Logo
Cerus Corp
NASDAQ:CERS
Watchlist
Price: 1.82 USD 3.41% Market Closed
Market Cap: 338m USD
Have any thoughts about
Cerus Corp?
Write Note

Cerus Corp
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cerus Corp
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Cerus Corp
NASDAQ:CERS
Gross Profit
$119.8m
CAGR 3-Years
11%
CAGR 5-Years
17%
CAGR 10-Years
22%
Haemonetics Corp
NYSE:HAE
Gross Profit
$735.3m
CAGR 3-Years
19%
CAGR 5-Years
10%
CAGR 10-Years
5%
ICU Medical Inc
NASDAQ:ICUI
Gross Profit
$769.1m
CAGR 3-Years
17%
CAGR 5-Years
9%
CAGR 10-Years
18%
Align Technology Inc
NASDAQ:ALGN
Gross Profit
$2.8B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
17%
Lantheus Holdings Inc
NASDAQ:LNTH
Gross Profit
$969.6m
CAGR 3-Years
78%
CAGR 5-Years
41%
CAGR 10-Years
25%
Merit Medical Systems Inc
NASDAQ:MMSI
Gross Profit
$620.9m
CAGR 3-Years
10%
CAGR 5-Years
8%
CAGR 10-Years
11%
No Stocks Found

Cerus Corp
Glance View

Market Cap
337.8m USD
Industry
Health Care

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

CERS Intrinsic Value
1.56 USD
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Cerus Corp's Gross Profit?
Gross Profit
119.8m USD

Based on the financial report for Sep 30, 2024, Cerus Corp's Gross Profit amounts to 119.8m USD.

What is Cerus Corp's Gross Profit growth rate?
Gross Profit CAGR 10Y
22%

Over the last year, the Gross Profit growth was 3%. The average annual Gross Profit growth rates for Cerus Corp have been 11% over the past three years , 17% over the past five years , and 22% over the past ten years .

Back to Top